Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Mark the K who wrote (5005)	7/22/1998 3:49:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 7041

Mark, the mild ED data could be seen checking the "news" item at the top of the thread, one of the last companies reports. It is mentioned at the end, I did not noticed it until couple of days ago when I reread it. The mil ED data seems to be similar to last year report that got the stock to the $40s, but at the time it was a partial report of the mild cases without referring to this data as the mild cases, this was a clear manipulation of the information, cause the same numbers plus the "overall" came from the same two phase III US studies, but it seems that they could not get away with it at the California conference, there the "peers" usually require all the numbers in a presentation. Obviuously they did not generated the enthusiasm of the first time, and actually created distribution of the stock, this with the Schering agreement on board and the NDA application on.